Benzinga

Benzinga

Benzinga

samedi, septembre 05

ARS Pharmaceuticals Inc

SPRYNASDAQ
Trade with Public
Trade with Public
$5.62
-0.05-0.88%
À la clôture: Sep 4, 5:00 PM EST
$5.60
-0.02-0.36%
Après les heures: 7:59 PM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerOptionsRapport sur les stocks

ARS Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for ARS Pharmaceuticals (SPRY).

Price Target Range — 8 Quarters

Analyst Consensus — 6 Analysts

1S.Buy
4Buy
1Hold
Consensus RatingOutperform# Analysts6Avg. Consensus PT$29Upside to Avg. PT+408.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jun 25, 2026Leerink PartnersRoanna RuizPT CutOutperform$25→$24
May 28, 2026Cantor FitzgeraldJosh SchimmerPT RaiseOverweight$12→$30
More with Benzinga EdgeGet Access

Analyst Ratings News

Can ARS Pharma's New CEO Unlock Neffy's Potential?

ARS Pharma (SPRY) co-founder Richard Lowenthal steps down as CEO. President Donn Casale succeeds him amid a strategic shift.
Vandana Singh

ARS Pharma Reaffirms 2027 Breakeven Goal Despite Missing July Neffy Coverage Wins

ARS Pharma reaffirmed its 2027 breakeven target, cut expenses and gained Florida Medicaid access for Neffy despite coverage setbacks.
Vandana Singh

PRO
Leerink Partners Maintains Outperform on ARS Pharmaceuticals, Lowers Price Target to $24

Leerink Partners analyst Roanna Ruiz maintains ARS Pharmaceuticals (NASDAQ:SPRY) with a Outperform and lowers the price target from $25 to $24.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on ARS Pharmaceuticals, Raises Price Target to $30

Cantor Fitzgerald analyst Josh Schimmer maintains ARS Pharmaceuticals (NASDAQ:SPRY) with a Overweight and raises the price target from $12 to $30.
Benzinga Newsdesk

ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) to release first quarter earnings on May 15 before opening bell. Analysts expect a loss of 54 cents per share.
Avi Kapoor

Bad News For Competitor Turns Into Big Win For ARS Pharma Stock

ARS Pharmaceuticals Inc. stock rose Friday as FDA identified deficiencies in rival Aquestive's application, delaying potential competition.
Vandana Singh

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved